top of page


Eli Lilly agrees to acquire Calytrix Bio for up to $1.5 billion to expand rare blood cancer pipeline
Eli Lilly has agreed to acquire Calytrix Bio for up to $1.5 billion, adding a preclinical antibody programme targeting mutant calreticulin in rare myeloproliferative blood disorders.

nuaxia
1 hour ago2 min read


Eli Lilly partners with Hims & Hers to expand access to Zepbound and Foundayo obesity medicines
Lilly's commercial partnership with Hims & Hers brings two FDA-approved obesity treatments into an integrated telehealth prescribing and delivery pathway, with published self-pay starting prices from $149 per month.

nuaxia
Nov 92 min read


Eli Lilly partners with METiS TechBio in AI-driven lipid nanoparticle collaboration worth up to $1.1 billion in milestones
Eli Lilly and METiS TechBio have entered an AI-enabled lipid nanoparticle discovery collaboration carrying up to approximately $1.1 billion in potential milestone payments.

nuaxia
Oct 212 min read


Lilly expands Gate Bioscience collaboration for molecular-gate protein degraders
Eli Lilly and Gate Bioscience have expanded their drug-discovery collaboration by adding a new target and an option for a second under Gate's Molecular Gate platform.

nuaxia
Oct 72 min read


FDA expands Jaypirca approval to first-line treatment of CLL and SLL
The FDA has moved Jaypirca into first-line CLL and SLL treatment following Phase III data showing a substantial reduction in the risk of disease progression or death.

nuaxia
Oct 52 min read


FDA expands Olumiant approval to adolescents with severe alopecia areata
The expanded indication extends Lilly's JAK inhibitor to adolescents aged 12 years and older with severe alopecia areata.

nuaxia
Sep 281 min read


Lilly and InnoCare sign drug-discovery collaboration worth up to $3.35bn
Lilly and InnoCare have entered a multi-target research and licensing collaboration potentially worth $3.35 billion to discover and develop new medicines.

nuaxia
Sep 252 min read


FDA approves Onswik as once-weekly basal insulin for adults with type 2 diabetes
The FDA has approved Lilly's Onswik as a once-weekly basal insulin for adults with type 2 diabetes, reducing the frequency of basal insulin injections from daily to weekly dosing.

nuaxia
Sep 252 min read


FDA approves Inluriyo plus Verzenio for ESR1-mutated advanced breast cancer
The FDA has approved Inluriyo in combination with Verzenio for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer following progression on endocrine therapy.

nuaxia
Sep 212 min read


Lilly and QurCan enter genetic-medicine collaboration worth up to $237m per programme
Lilly and QurCan Therapeutics have entered a multi-programme collaboration to develop nucleic-acid medicines for central and peripheral nervous system diseases using QurCan's TERP delivery platform.

nuaxia
Sep 162 min read


Lilly agrees acquisition of Merida Biosciences in deal worth up to $2.875bn
Lilly’s planned acquisition of Merida Biosciences adds an antibody-engineering platform designed to selectively remove disease-causing antibodies while preserving normal immune function.

nuaxia
Sep 12 min read


Eli Lilly Builds Infectious Disease Platform with Three-Acquisition Strategy
The company expands into vaccine-led prevention as pharma shifts focus toward long-term disease risk reduction driven by infection-linked chronic outcomes and antimicrobial resistance.

nuaxia
May 303 min read
bottom of page